Testosterone Cream for Women — Women's Hormones

Transdermal testosterone therapy for sexual dysfunction and quality of life in perimenopausal and postmenopausal women. Grade B evidence from multiple RCTs.

Overview

Testosterone therapy in women addresses symptoms of androgen deficiency including low libido, fatigue, decreased motivation, and cognitive fog. The Global Consensus Position Statement (2019) and Cochrane Review (2020) of 36 RCTs (8,480 women) support testosterone for postmenopausal women with hypoactive sexual desire disorder (HSDD). Transdermal cream is preferred over oral or injectable routes. While not FDA-approved for women in the US, testosterone is widely used off-label with endorsement from international menopause societies.

Indications

  • Hypoactive Sexual Desire Disorder (HSDD) in peri/postmenopausal women
  • Low libido unresponsive to estrogen therapy alone
  • Fatigue and decreased energy in menopause
  • Cognitive symptoms (brain fog) during menopause transition
  • Decreased motivation and sense of well-being

Mechanism of Action

Testosterone cream absorbed through skin, bypassing hepatic first-pass metabolism

Dosing

CompoundDoseFrequencyNotes
Compounded Testosterone Cream0.5 mg/dayApply dailyStarting dose. Apply to inner thigh, labia majora, or forearm. Compounded 0.5% cream
Compounded Testosterone Cream1.0 mg/dayApply dailyTypical therapeutic dose. 1% cream (1mg per 0.1mL application)
Compounded Testosterone Cream2.0 mg/dayApply dailyUpper limit for physiologic replacement. Rarely needed; monitor for androgenic effects

Evidence Grade

GRADE B

Safety & Contraindications

  • NOT FDA-approved for women - off-label use supported by international guidelines
  • Transdermal cream preferred over oral (avoid first-pass liver metabolism)
  • Monitor for androgenic effects: acne, hirsutism, voice deepening (rare at physiologic doses)
  • Aim for premenopausal female testosterone levels, NOT supraphysiologic
  • Contraindicated with active breast cancer, pregnancy, or androgen-sensitive conditions
  • Use in conjunction with estrogen/progesterone HRT for best results
  • Long-term safety data (>2 years) limited but reassuring short-term profiles